# Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

> **NCT04796324** · PHASE2 · TERMINATED · sponsor: **Allarity Therapeutics** · enrollment: 13 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Ixabepilone Injection

## Key facts

- **NCT ID:** NCT04796324
- **Lead sponsor:** Allarity Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04796324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04796324, "Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04796324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*